Articles |
the Department of Radiology (I.M.F., S.H.) of the Warren G. Magnuson Clinical Center of the National Institutes of Health and the Molecular Disease Branch (K.A.D., S.S.-F., H.B.B., J.M.H.) and the Office of Biostatistics Research (J.S.), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.
Correspondence to Jeffrey M. Hoeg, Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bldg 10, Rm 7N115, 10 Center Dr, MSC 1666, Bethesda, MD 20892-1666. E-mail jeff@mdb.nhlbi.nih.gov.
Homozygous familial hypercholesterolemia (FH) is a rare genetic disorder that leads to premature atherosclerosis due to a defective LDL receptor. There is, however, a large degree of phenotypic heterogeneity at the level of atherosclerosis even in patients with identical mutations of the LDL receptor protein. Lipoprotein lipase (LPL) and hepatic lipase (HL) are crucial enzymes in lipoprotein metabolism, and both have been proposed as having proatherogenic as well as antiatherogenic effects. To evaluate a potential role for these enzymes in the severity of atherosclerosis, we correlated postheparin LPL mass and activity as well as HL activity with the volume of total calcific atherosclerosis (heart and thoracic aorta), coronary artery calcific atherosclerosis, and Achilles tendon width as measured by computed tomography in 15 FH homozygotes. LPL dimer and total mass were positively correlated with all three parameters (r=.65 to .87, P<.01) as was LPL activity (r=.52 to .63, P<.05). HL activity was negatively correlated with total and coronary artery calcified lesion volume (r=-.55 to .57, P<.05). In a multiple regression model of the coronary artery lesion volume, LPL dimer mass and HL activity together accounted for 84% of the variability (r=.92, P<.0001). In a multiple regression model of the total calcified lesion volume, HL activity, total cholesterol, age, and LPL dimer mass together accounted for 85% of the variability (r=.92, P=.0005). These data demonstrate a significant correlation of LPL mass and activity with the extent of calcific atherosclerosis in homozygous FH. It is not clear whether LPL is the cause or consequence of the observed correlation, but if the association between LPL and coronary artery lesions is also present in patients with other genetic dyslipoproteinemias, LPL could constitute a new risk factor for cardiovascular disease.
Key Words: atherosclerosis coronary disease macrophages computed tomography x-ray xanthomatosis
This article has been cited by other articles:
![]() |
T. J. Orchard, T. Costacou, A. Kretowski, and R. W. Nesto Type 1 diabetes and coronary artery disease. Diabetes Care, November 1, 2006; 29(11): 2528 - 2538. [Full Text] [PDF] |
||||
![]() |
T. Koike, J. Liang, X. Wang, T. Ichikawa, M. Shiomi, H. Sun, T. Watanabe, G. Liu, and J. Fan Enhanced aortic atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits expressing lipoprotein lipase Cardiovasc Res, February 1, 2005; 65(2): 524 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Jansen, A. J. M. Verhoeven, and E. J. G. Sijbrands Hepatic lipase: a pro- or anti-atherogenic protein? J. Lipid Res., September 1, 2002; 43(9): 1352 - 1362. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Hokanson, S. Cheng, J. K. Snell-Bergeon, B. A. Fijal, M. A. Grow, C. Hung, H. A. Erlich, J. Ehrlich, R. H. Eckel, and M. Rewers A Common Promoter Polymorphism in the Hepatic Lipase Gene (LIPC-480C>T) Is Associated With an Increase in Coronary Calcification in Type 1 Diabetes Diabetes, April 1, 2002; 51(4): 1208 - 1213. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Beauchamp, E. Letendre, and G. Renier Macrophage lipoprotein lipase expression is increased in patients with heterozygous familial hypercholesterolemia J. Lipid Res., February 1, 2002; 43(2): 215 - 222. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Dugi, K. Brandauer, N. Schmidt, B. Nau, J. G. Schneider, S. Mentz, T. Keiper, J. R. Schaefer, C. Meissner, H. Kather, et al. Low Hepatic Lipase Activity Is a Novel Risk Factor for Coronary Artery Disease Circulation, December 18, 2001; 104(25): 3057 - 3062. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Couture, J. D. Otvos, L. A. Cupples, C. Lahoz, P. W. F. Wilson, E. J. Schaefer, and J. M. Ordovas Association of the C-514T Polymorphism in the Hepatic Lipase Gene With Variations in Lipoprotein Subclass Profiles : The Framingham Offspring Study Arterioscler Thromb Vasc Biol, March 1, 2000; 20(3): 815 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Boedeker, M. Doolittle, S. Santamarina-Fojo, and A. L. White Role of N-linked carbohydrate processing and calnexin in human hepatic lipase secretion J. Lipid Res., September 1, 1999; 40(9): 1627 - 1635. [Abstract] [Full Text] |
||||
![]() |
J. D. Medh, S. L. Bowen, G. L. Fry, S. Ruben, J. Hill, H. Wong, and D. A. Chappell Hepatic triglyceride lipase promotes low density lipoprotein receptor-mediated catabolism of very low density lipoproteins in vitro J. Lipid Res., July 1, 1999; 40(7): 1263 - 1275. [Abstract] [Full Text] |
||||
![]() |
C. F. Semenkovich, T. Coleman, and A. Daugherty Effects of heterozygous lipoprotein lipase deficiency on diet-induced atherosclerosis in mice J. Lipid Res., June 1, 1998; 39(6): 1141 - 1151. [Abstract] [Full Text] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |